<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124408">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934673</url>
  </required_header>
  <id_info>
    <org_study_id>INS-4066</org_study_id>
    <secondary_id>U1111-1138-8402</secondary_id>
    <nct_id>NCT01934673</nct_id>
  </id_info>
  <brief_title>A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia</brief_title>
  <acronym>DiabCare Asia</acronym>
  <official_title>A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Malaysia: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this non-interventional study is to evaluate the
      current status of diabetes management, control, and complications in subjects with type 2
      diabetes in Malaysia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Proportion of patients having HbA1c ((glycosylated haemoglobin) as measured during survey) less than 7%</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Fasting Plasma Glucose (FPG) of patients</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Postprandial Plasma Glucose (PPG) of  patients</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HbA1c of  patients</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of  patients having dyslipidemia</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having hypertension</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of  patients having cardiovascular complications</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of  patients having peripheral vascular disease</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of  patients having diabetic nephropathy</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of  patients having diabetic eye complications</measure>
    <time_frame>Evaluated at the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1667</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects with diabetes (type 2)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Patients will fill out a questionnaire by interview.</description>
    <arm_group_label>Subjects with diabetes (type 2)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People treated for at least a year are eligible for the study. The selection of the
        patients will be done randomly by the individual physician involved in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People with type 2 diabetes mellitus (DM) who are being treated, with any of the
             non-pharmacological or pharmacological options, at a particular centre for at least 2
             years and who have visited the centre within the last 3-6 months

          -  Patients willing to sign informed consent form

        Exclusion Criteria:

          -  Previous participation in this study

          -  Unable to comply with protocol requirements

          -  Confirmed or suspected pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasanna Kumar</last_name>
    <role>Study Director</role>
    <affiliation>NN Pharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Selangor Darul Ehsan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 5, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
